JPRN-UMIN000040599已完成2 期
Multicombination Therapy of Temozolomide, Vincristine, and Interferon-beta with Radiotherapy for Malignant Glioma - R-TVI trial
Department of Neurosurgery, Hirosaki University School of Medicine0 个研究点目标入组 50 人开始时间: 2020年5月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who did not satisfy inclusion criteria
研究者
相似试验
招募中
2 期
The therapeutic effect ofTemozolomide, Vincristine, Interferon-beta and Bevacizumab Combination Chemoradiotherapy for Malignant GliomasMalignant gliomaJPRN-UMIN000024209Department of Neurosurgery, Hirosaki University Graduate school of Medicine50
已完成
1 期
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseNon Small Cell Lung CancerCNS ProgressionNCT04541407University of Colorado, Denver1
已完成
不适用
Ketogenic diet as adiuvant treatment in adults with glioblastoma multiformeGlioblastoma Multiforme, ketogenic diet, feasbility, safety, adults, brain cancer, ketosisNL-OMON19917ErasmusMC12
已完成
不适用
Feasibility of standard therapy with temozolomide and radiotherapy combined with ketogenic diet in patients with glioblastoma multiformeGlioblastoma MultiformeNL-OMON40862Erasmus MC, Universitair Medisch Centrum Rotterdam15
进行中（未招募）
不适用
Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa studyEUCTR2004-004849-18-DEMerck KGaA50